Granted Patent
B2
US 12,734,188 · App. 18/580,779 · Granted Sep 15, 2026
Pharmaceutical composition comprising combination of sitagliptin and empagliflozin
Inventors:
Balvir Singh (Ahmedabad, IN); Ramesh Shingala (Ahmedabad, IN); Milap Patel (Gandhinagar, IN); Ritesh Patel (Ahmedabad, IN)
Assignee:
UNISON PHARMACEUTICALS PVT. LTD.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to a stable pharmaceutical composition comprising a fixed dose combination of a therapeutically effective amount of DPP-IV inhibitor and a therapeutically effective amount of SGLT2 inhibitor for reducing blood glucose level in patients with diabetes. The present invention specifically relates to a stable pharmaceutical composition comprising Sitagliptin or a pharmaceutically acceptable salts or solvate or hydrate or premix thereof and Empagliflozin or a pharmaceutically acceptable salt or solvate or hydrate or premix thereof in the presence of one or more pharmaceutically acceptable excipients. Moreover, the present invention relates to a stable pharmaceutical composition comprising Sitagliptin Phosphate Monohydrate, Empagliflozin and one or more pharmaceutically acceptable excipients with high content uniformity, reduced degradation impurities and optimum dissolution.
Claims (8)
1 . A stable pharmaceutical composition comprising a combination of Sitagliptin or pharmaceutically acceptable salt or solvate thereof with Empagliflozin or pharmaceutically acceptable salt or solvate thereof and at least one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition comprises a first portion and a second portion, wherein the first portion comprises Sitagliptin or pharmaceutically acceptable salt or solvate thereof in the form of powder or granules along with one or more pharmaceutically acceptable excipients, and the second portion comprises Empagliflozin or pharmaceutically acceptable salt or solvate thereof in the form of powder or granules along with one or more pharmaceutically acceptable excipients.
2 . The stable pharmaceutical composition as claimed in claim 1 , wherein the composition is in the form of single layer or bilayer tablet.
3 . The stable pharmaceutical composition as claimed in claim 2 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of diluent, binder, disintegrant, stabilizer, lubricant, glidant, colouring agent, film coating agent and a combination thereof.
4 . The stable pharmaceutical composition as claimed in claim 3 , wherein the composition, when stored at 40° C. and 75% relative humidity, contains not more than 0.2% of any known or unknown impurity and not more than 2% of the total impurity for Sitagliptin; and contains not more than 0.5% of any known impurity, not more than 0.2% of any unknown impurity and not more than 2% of total impurity for Empagliflozin.
5 . The stable pharmaceutical composition as claimed in claim 1 , wherein at least 75% of Sitagliptin and Empagliflozin are released within 30 minutes.
6 . The stable pharmaceutical composition as claimed in claim 1 , wherein the composition comprises 10-40% w/w Sitagliptin, 1-10% w/w Empagliflozin, 5-80% w/w of diluent, 1-10% w/w of disintegrant, 1-10% w/w binder, 0-10% w/w stabilizer, 0.1-5% lubricant, 0.1-5% w/w glidant and 1-10% w/w of film former of the total weight of the composition.
7 . The stable pharmaceutical composition as claimed in claim 6 , wherein the stabilizer is selected from the group consisting of acidic agent, alkalizing agent, buffering agent, amino acid, anti-oxidant, and a combination thereof.
8 . The stable pharmaceutical composition as claimed in claim 7 , wherein the stabilizer is L-Arginine.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 21, 2024
From: SINGH, BALVIR; SHINGALA, RAMESH; PATEL, MILAP; PATEL, RITESH
To: UNISON PHARMACEUTICALS PVT. LTD.
Reel/Frame 066190/0648 →
Priority Claims (1)
IN 202121046486
· Oct 12, 2021
· national
Continuity (1)
References Cited (127)
US 6414126B1
· Ellsworth et al.
· 2002
[cited by applicant]
US 7407955B2
· Himmelsbach et al.
· 2008
[cited by applicant]
US 7515117B2
· Moon
· 2009
[cited by applicant]
US 8221786B2
· Bindra et al.
· 2012
[cited by applicant]
US 20110098240A1
· Dugi et al.
· 2011
[cited by applicant]
US 20130224296A1
· Narang et al.
· 2013
[cited by applicant]
US 20140079778A1
· Narang et al.
· 2014
[cited by applicant]
US 20150283248A1
· Jayaramareddy et al.
· 2015
[cited by applicant]
US 20170319539A1
· Jetti et al.
· 2017
[cited by applicant]
US 20190110994A1
· Shervi et al.
· 2019
[cited by applicant]
CN 109549939A
· 2019
[cited by applicant]
CN 112716966A
· 2021
[cited by applicant]
IN 201721036839
· 2019
[cited by applicant]
IN 201741023337
· 2019
[cited by applicant]
KR 20190040765A
· 2019
[cited by applicant]
WO WO2008002824A1
· 2008
[cited by applicant]
WO WO2009022008A1
· 2009
[cited by applicant]
WO WO2009022009A1
· 2009
[cited by applicant]
WO WO2009022010A1
· 2009
[cited by applicant]
WO WO2009091082A1
· 2009
[cited by applicant]
WO WO2010092124A1
· 2010
[cited by applicant]
WO WO2010092125A1
· 2010
[cited by applicant]
WO WO2012120040A1
· 2012
[cited by applicant]
WO WO2011002011A1
· 2012
[cited by applicant]
WO WO2014080383A1
· 2014
[cited by applicant]
WO WO2014083554A1
· 2014
[cited by applicant]
WO WO2015173584A1
· 2015
[cited by applicant]
WO WO2018124468A1
· 2018
[cited by applicant]
WO WO2018124497A1
· 2018
[cited by applicant]
WO WO2019120162A1
· 2019
[cited by applicant]
WO WO2019221473A1
· 2019
[cited by applicant]
WO WO2020009675A2
· 2020
[cited by applicant]
WO WO2020018034A2
· 2020
[cited by applicant]
WO WO2020058095A1
· 2020
[cited by applicant]
WO WO2020106020A1
· 2020
[cited by applicant]
WO WO2020130502A1
· 2020
[cited by applicant]
WO WO2021176096A1
· 2021
[cited by applicant]
WO WO2021218638A1
· 2021
[cited by examiner]
Lobmann et al. (Amino acids as co-amorphous stabilizers for poorly water soluble drugs—Part 1: Preparation, stability and dissolution enhancement), European Journal of Pharmaceutics and Biopharmaceutics 85 (2013) 873-88…
[cited by examiner]
U.S. Appl. No. 18/580,748, filed Jan. 19, 2024.
[cited by applicant]
Abdel-Ghany et al., “Pharmaceutical Analysis of Linagliptin and Empagliflozin using LC-MS/MS.”
[cited by applicant]
Abdul-Ghani, “Where Does Comination Therapy With an SGLT2 Inhibitor Plus a DPP-4 Inhibitor Fit in the Management of Type 2 Diabetes?”,
[cited by applicant]
Al Ameri et al., “The Implications of Fixed Dose Combination (FDC) Compared to Single Pill Combinations (SPC): Based on Patients' View.”
[cited by applicant]
Aronson, “Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.”
[cited by applicant]
Babu et al., “Novel Stress Indicating RP-HPLC Method Development and Validation for the Simultaneous Estimation of Ertugliflozin and Sitagliptin in Bulk and its Formulation.”
[cited by applicant]
Basile, “A New Approach to Glucose Control in Type 2 Diabetes: The Role of Kidney Sodium-Glucose Co-transporter 2 Inhibition.”
[cited by applicant]
Benford et al., “Fixed-Dose Combination Antidiabetic Therapy: Real-World Factors Associated with Prescribing Choices and Relationship with Patient Satisfaction and Compliance.”
[cited by applicant]
Bhole et al., “Stability Indicating HPTLC Method for Simultaneous Estimation of Empagliflozin and Linagliptin in Pharmaceutical Formulation,”
[cited by applicant]
Boulton et al., “Simultaneous oral therapeutic and intravenous 14C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin.”
[cited by applicant]
Brand et al., “Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter-2 (SGLT-2), Coadministered with Sitagliptin in Healthy Volunteers”
[cited by applicant]
Cai et al., “Characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large US claims database,”
[cited by applicant]
Charokopou et al., “Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.”
[cited by applicant]
Chen et al., “Effects of Combining Linagliptin Treatment with BI-38335, A Novel SGLT2 Inhibitor, on Pancreatic Islet Function and Inflammation in db/db Mice.”
[cited by applicant]
Cholke et al., “Comparative Study of Two Different Marketed Preparation (Tablets) Containing Empagliflozin and Linagliptin and Developing Novel Method for Simultaneous Estimation of Empagliflozin and Linagliptin Using U…
[cited by applicant]
Coppenrath et al., “Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes.”
[cited by applicant]
DeFronzo et al., “Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin.”
[cited by applicant]
Dey, “SGLT2 inhibitor/DPP-4 inhibitor combination therapy—complementary mechanisms of action for management of type 2 diabetes mellitus,”
[cited by applicant]
Ekholm et al., “Combined Treatment With Saxagliptin Plus Dapagliflozin Reduces Insulin Levels by Increased Insulin Clearance and Improves β-Cell Function.”
[cited by applicant]
Forst et al., “Effects of sequentially adding empagliflozin and linagliptin on alpha and beta cell function in type 2 diabetic patients on previous metformin treatment—An exploratory mechanistic study.”
[cited by applicant]
Forst et al., “Clinical overview of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with Type 2 diabetes mellitus.”
[cited by applicant]
Friedrich et al., “A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetics of Empagliflozin and Linagliptin After Coadministration in Healthy Male Volunteers,”
[cited by applicant]
“GLYXAMBI® (empagliflozin and linagliptin) tablets, for oral use.” 1-33 (Dec. 2016).
[cited by applicant]
Guthrie, “Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus”,
[cited by applicant]
Hansen et al., “Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy.”
[cited by applicant]
Harris, “The power of two: An update on fixed-dose combinations for type 2 diabetes.”
[cited by applicant]
Hutchins et al., “A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes.”
[cited by applicant]
Indian Patent Office, International Search Report in International Patent Application No. PCT/IN2022/050665, mailed Oct. 25, 2022, 3 pp.
[cited by applicant]
Indian Patent Office, International Search Report in International Patent Application No. PCT/IN2022/050908, mailed Jan. 18, 2023, 3 pp.
[cited by applicant]
Indian Patent Office, Written Opinion in International Patent Application No. PCT/IN2022/050665, mailed Oct. 25, 2022, 4 pp.
[cited by applicant]
Indian Patent Office, Written Opinion in International Patent Application No. PCT/IN2022/050908, mailed Jan. 18, 2023, 6 pp.
[cited by applicant]
Jabbour et al., “Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.”
[cited by applicant]
Jain, “Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus.”
[cited by applicant]
Jay et al., “RP-HPLC Method Development and Validation for Estimation of Dapagliflozin Propanediol Monohydrate and Sitagliptin From Synthetic Mixture.”
[cited by applicant]
Jojima et al., “Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes.”
[cited by applicant]
Kalra et al., “Fixed-dose combination in management of type 2 diabetes mellitus: Expert opinion from an international panel.”
[cited by applicant]
Kasahara et al., “Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.”
[cited by applicant]
Kasichayanula et al., “Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.”
[cited by applicant]
Katsiki et al., “Fixed-dose combination of empagliflozin and linagliptin for the treatment of patients with type 2 diabetes mellitus: A systematic review and meta- analysis.”
[cited by applicant]
Kaushal et al., “Clinical Safety and Recent Patents on Fixed-Dose Combinations of DPP-4 Inhibitors: an Updated Review.”
[cited by applicant]
Kelleni, “Gliflozins: initial review of litera”,
[cited by applicant]
Kim et al., “Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.”
[cited by applicant]
Lajara, “Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes,”
[cited by applicant]
Lavalle-González et al., “Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.”
[cited by applicant]
Lewin et al., “Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes.”
[cited by applicant]
Mathieu et al., “A Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.”
[cited by applicant]
Matthaei et al., “A Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes.”
[cited by applicant]
Miller et al., “Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The Vertis Sita Randomized Study.”
[cited by applicant]
Musso et al., “A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials.”
[cited by applicant]
Nizami et al., “Analytical method development and validation for simultaneous estimation of Ipragliflozin and Sitagliptin in tablet form by RP-HPLC method.”
[cited by applicant]
Oguma et al., “Changes in glucose-induced plasma active glucagon-like peptide-1 levels by co-administration of sodiumeglucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors in rodents.”
[cited by applicant]
Phani et al., “A Study of New Method Development, Validation and Forced Degradation for Simultaneous Analysis of Dapagliflozin and Saxagliptin in Pharmaceutical Dosage Form by HPLC Method.”
[cited by applicant]
Pratley et al., “Ertugliflozin Plus Sitagliptin Versus Either Individual Agent Over 52 Weeks in Patients with Type 2 Diabetes Mellitus Inadequately Controlled With Metformin: The Vertis Factorial Randomized Trial.”
[cited by applicant]
“QTERN® (dapagliflozin and saxagliptin) tablets, for oral use.” 1-42 (Feb. 2017).
[cited by applicant]
Rizk et al., “Validated Voltammetric Method for the Simultaneous Determination of Anti-diabetic Drugs, Linagliptin and Empagliflozin in Bulk, Pharmaceutical Dosage Forms and Biological Fluids,”
[cited by applicant]
Rizos et al., “Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.”
[cited by applicant]
Roden et al., “Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.”
[cited by applicant]
Rosenstock et al., “Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin o…
[cited by applicant]
Satoh-Asahara et al., “A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients”
[cited by applicant]
Scheen, “Drug-Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus.”
[cited by applicant]
Scheen, “Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.”
[cited by applicant]
Scheen, “SGLT2 Inhibitors: Benefit/Risk Balance,”
[cited by applicant]
Scheen, “Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations.”
[cited by applicant]
Scheen, “DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects”,
[cited by applicant]
Scheen, “A review of gliptins in 2011.”
[cited by applicant]
Scheen, “Dapagliflozin and Saxagliptin Tablets for Adults with Type 2 Diabetes.”
[cited by applicant]
Scheen et al., “Gliptin-gliflozin combination in the treatment of type 2 diabetes”,
[cited by applicant]
Sharma, “Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes”,
[cited by applicant]
Sheikh et al., “Development and Validation of Rapid Stability-Indicating High-Performance Liquid Chromatography Method for the Determination of Linagliptin and Empagliflozin in Pure and Dosage Forms.”
[cited by applicant]
Singh et al., “Sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors combination therapy in type 2 diabetes: A systematic review of current evidence,”
[cited by applicant]
Smulders et al., “No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.”
[cited by applicant]
Søfteland et al., “Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial.”
[cited by applicant]
Tahara et al., “Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice.”
[cited by applicant]
Tan et al., “Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes.”
[cited by applicant]
Terauchi et al., “Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-…
[cited by applicant]
Tinahones et al., “Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: two 24-week randomized, double-blind, double-dummy, parallel-group trials.”
[cited by applicant]
Triplitt et al., “Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.”
[cited by applicant]
Vakkalagadda et al., “Lack of a Pharmacokinetic Interaction Between Saxagliptin and Dapagliflozin in Healthy Subjects: A Randomized Crossover Study.”
[cited by applicant]
Vakkalagadda et al., “Bioequivalence of saxagliptin/dapagliflozin fixed-dose combination tablets compared with coadministration of the individual tablets to healthy subjects.”
[cited by applicant]
Vaseem et al., “SGLT2 Inhibitor and DPP4 Inhibitor Co-Administration in Type 2 Diabetes—Are We Near The ‘Promised Land’?”,
[cited by applicant]
Williams et al., “Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetes.”
[cited by applicant]
Woo, “Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option.”
[cited by applicant]
Zinman, “Initial Combination Therapy for Type 2 Diabetes Mellitus: Is It Ready for Prime Time?.”
[cited by applicant]